Results of the Relieva® Clinical Trial in Eczema Treatment Published

• ShareThis Email PDF Print

Eczema is a cruel disease that is often mistaken as just a rash but can have a profound impact on patients' quality-of-life and emotional well-being, particularly in children. It not only afflicts the patients, their friends and family are also affected by the emotional impact

Oldsmar, FL (PRWEB) November 28, 2007

The results of the study conducted in the USA. to determine the efficacy and tolerability of Relieva® in adult patients with Atopic Dermatitis (eczema) were just published in the September issue of the American Journal of Therapeutics (14:442-446, 2007).

Previous laboratory studies showed that Psorberine®, the active ingredient of Relieva®, a non-corticoid, non- immunosuppressant but potent anti-inflammatory compound might be effective in atopic dermatitis. A clinical trial was conducted to determine if indeed Relieva® is efficacious in these patients.

Patients enrolled in this 12 week trial carried out by Global Clinicals Inc. were treated with Relieva®, a topical preparation containing Psorberine in Novasome®, a proprietary liposome formulation. Efficacy and safety was assessed using EASI (Eczema Area and Severity Index), an established index used for evaluating the severity of the signs of atopic dermatitis and a Subject Reported Evaluation of Treatment.
Study results showed significant improvements in Erythema, Infiltration, Excoriation and Lichenification scores. In addition, subjects responding to a post treatment evaluation questionnaire indicated a substantial benefit when rating effectiveness, itching and appearance.

This study indicates that Relieva® is useful in adult patients with atopic dermatitis.

Apollo Pharmaceuticals continuous research in dermatology offers another option for the treatment of adult patients with Atopic Dermatitis (eczema).

About Eczema
"Eczema is a cruel disease that is often mistaken as just a rash but can have a profound impact on patients' quality-of-life and emotional well-being, particularly in children. It not only afflicts the patients, their friends and family are also affected by the emotional impact"`.

Eczema affects approximately 17% of the U.S. population and is often a distressing condition characterized by itchy, scaly, dry, inflamed skin. It is estimated that 90% of eczema patients experience symptoms before the age of 5. Many patients, especially children, experience a significant emotional impact, feeling 'different'and/or left out. Feelings of social isolation and lack of sleep due to night-time itching demonstrate of how eczema impacts a patient's daily live.

A global study comprised of interviews with 2,002 patients from eight countries over the age of 13, and caregivers of children between the ages of 2-13, with moderate to severe eczema showed that on average, 86% of patients avoid at least one type of everyday activity during a flare-up and 74% of patients and caregivers state that their physicians have never discussed the emotional impact that eczema has had on their lives. (http://www.nationaleczema.org)

###

Share: